DaVita Clinical Research Presents Research Results at the American Nephrology Nurses Association National Symposium

  DaVita Clinical Research Presents Research Results at the American
  Nephrology Nurses Association National Symposium

Business Wire

LAS VEGAS -- April 22, 2013

DaVita Clinical Research^® (DCR^®) (NYSE: DVA), a specialty contract research
organization with services spanning the full spectrum of drug and device
development, today announced that company representatives will present four
abstracts at the American Nephrology Nurses Association (ANNA) National
Symposium scheduled for April 21-24, 2013 in Las Vegas, Nevada.

With a membership of more than 10,000 registered nurses and other health care
professionals, the mission of ANNA is to promote excellence in nephrology
nursing and appreciation of the profession in order to make a positive
difference for people with kidney disease.

Researchers from DaVita®, the dialysis division of DaVita Healthcare Partners
Inc., and DCR will present results from a number of innovative clinical
improvement programs originating from DaVita and its research partners.

“At DaVita, we’re committed to furthering education and improving clinical
outcomes, which we feel is reflected in our studies,” said Mahesh Krishnan,
M.D., M.P.H., M.B.A., F.A.S.N., vice president of clinical research at DaVita.
“It’s ideal to present these findings at ANNA, where health care professionals
collaborate on ways to improve the quality of life for kidney patients.”

At this year's ANNA meeting, researchers from DCR and DaVita will focus on
several key research initiatives in end-stage renal disease, including:

  *“Decreasing Peritonitis Rate in Peritoneal Dialysis Resulting in Lower
    Mortality and Technique Failure” Oral presentation by Tracey Milligan,
    DaVita regional operations director, on Monday, April 22, in Abstract
    Concurrent Session #161, from 5:40 p.m. – 5:55 p.m.
  *“Extracellular Volume Control in Dialysis Patients to Reduce
    Hospitalizations.” Oral presentation by Irina Goykhman, vice president of
    clinical improvement at DaVita, on Monday, April 22, in Abstract
    Concurrent Session #162, from 5:20 p.m. – 5:35 p.m.
  *“Hemoglobin Trends in Incident End-Stage Renal Disease Patients from
    2008-2012” Poster presentation by Deuzimar Kulawik, director, office of
    the chief medical officer at DaVita
  *“Implementation of Electrolytically-Produced Sodium Hypochlorite Protocol
    Improved Peritonitis Rates” Poster presentation by Tracey Milligan

DCR provides a collaborative bridge between DaVita’s health care community and
the academic, pharmaceutical and biotech research community. DCR and DaVita
share a dedication to improving the health and quality of life for kidney care
patients.

To learn more about DCR and upcoming clinical trials, please visit
www.ParticipateDaVita.com.

DaVita, DaVita Clinical Research, DCR and DaVita HealthCare Partners are
trademarks or registered trademarks of DaVita Healthcare Partners Inc. All
other trademarks are the property of their respective owners.

About DaVita

DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune
500® company that, through its operating divisions, provides a variety of
health care services to patient populations throughout the United States and
abroad. A leading provider of kidney care in the United States, DaVita
delivers dialysis services to patients with chronic kidney failure and end
stage renal disease. DaVita strives to improve patients’ quality of life by
innovating clinical care, and by offering integrated treatment plans,
personalized care teams and convenient health-management services. As of
Dec.31, 2012, DaVita operated or provided administrative services at 1,954
outpatient dialysis centers located in the United States serving approximately
153,000 patients. The company also operated 36 outpatient dialysis centers
located in eight countries outside the United States. DaVita supports numerous
programs dedicated to creating positive, sustainable change in communities
around the world. The company’s leadership development initiatives and social
responsibility efforts have been recognized by Fortune, Modern Healthcare,
Newsweek and WorldBlu. For more information, please visit DaVita.com.

About DaVita Clinical Research

DaVita Clinical Research(DCR), a wholly owned subsidiary ofDaVita HealthCare
Partners Inc., uses its extensive, applied database and real-world healthcare
experience to assist pharmaceutical and medical device companies in the
design, recruitment, and completion of clinical trials including retrospective
and prospective pragmatic trials.DCR’s scientific and clinical expertise
spans the lifecycle of product development with more than 150 client
companies. DCR’sBiorepository,Early Clinical Researchunit (Phase I-IIa)
andClinical Development (Phase IIb through post-marketing)network of
physicians and investigative sites, data research,Health Economics & Outcomes
Research,Central Laboratory, andMedical Communicationsare focused on
providing world-class research in both complex/specialty populations and
therapeutic areas, and especially in CKD and ESRD populations. To learn more
about DCR, visitwww.davitaclinicalresearch.com.

Contact:

DaVita Clinical Research
Media:
Bianca Violante
Office: 303-876-6614
Mobile: 443-417-6044
Bianca.Violante@DaVita.com